Comparative Effectiveness News In Brief
AHRQ updating CER report on off-label atypical antipsychotic use: The Agency for Healthcare Research and Quality is performing a routine update to its Jan. 17, 2007, comparative effectiveness 1review of the off-label use of atypical antipsychotics. The agency, in a comment request on its 2Web site, notes that since the original report was published, "some important changes have occurred and part of the conclusions of the original report might be out of date." Among the changes highlighted are the availability of new studies, including randomized control trials, that have provided more efficacy evidence on off-label use of atypicals; new off-label uses have been identified; previous off-label uses have become approved uses; and new or increased adverse effects of off-label indications have been observed. Comments are being accepted until Feb. 9
You may also be interested in...
Congress took steps in its final version of the economic stimulus package to alleviate concerns that the comparative effectiveness research provisions will lead to the government making cost-based comparisons or making coverage and reimbursement decisions based on the research
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials